Objectives: To assess the prevalence of acquired drug resistance in HIV-1-infected patients living in Monrovia, Liberia, who had clinical and/or immunological failure of first-line ART according to WHO criteria. Patients and methods: Patients receiving ART for.1 year with clinical and/or immunological failure were included. Sequencing of protease and reverse transcriptase regions was performed using Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS) procedures and sequences were interpreted using the ANRS resistance algorithm. Results: Ninety patients were enrolled. They had been receiving ART for a median time of 42 months and half were receiving zidovudine/lamivudine/nevirapine. Seventy-five per cent of patients we...
Objective: To evaluate the extent of HIV-1 drug resistance among drug naïve Kenyan individuals....
Introduction: Emergence of HIV-1 drug resistance may limit the sustained benefits of antiretroviral ...
Background.Human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of ant...
Objectives: To assess the prevalence of acquired drug resistance in HIV-1-infected patients living i...
International audienceObjectives - To assess the prevalence of acquired drug resistance in HIV-1-inf...
International audienceObjectives - To assess the prevalence of acquired drug resistance in HIV-1-inf...
International audienceObjectives - To assess the prevalence of acquired drug resistance in HIV-1-inf...
Objective: This study aims to investigate the prevalence and types of drug resistance mutations amon...
Background: With widespread use of antiretroviral (ARV) drugs in Africa, one of the major potential ...
Objectives: Estimating the prevalence of accumulated HIV drug resistance in patients receiving antir...
Objectives: Estimating the prevalence of accumulated HIV drug resistance in patients receiving antir...
Background. Human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of an...
Objectives: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Sa...
Objectives: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Sa...
Objectives: To determine prevalence and predictors of antiretroviral drug resistance in newly diag-n...
Objective: To evaluate the extent of HIV-1 drug resistance among drug naïve Kenyan individuals....
Introduction: Emergence of HIV-1 drug resistance may limit the sustained benefits of antiretroviral ...
Background.Human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of ant...
Objectives: To assess the prevalence of acquired drug resistance in HIV-1-infected patients living i...
International audienceObjectives - To assess the prevalence of acquired drug resistance in HIV-1-inf...
International audienceObjectives - To assess the prevalence of acquired drug resistance in HIV-1-inf...
International audienceObjectives - To assess the prevalence of acquired drug resistance in HIV-1-inf...
Objective: This study aims to investigate the prevalence and types of drug resistance mutations amon...
Background: With widespread use of antiretroviral (ARV) drugs in Africa, one of the major potential ...
Objectives: Estimating the prevalence of accumulated HIV drug resistance in patients receiving antir...
Objectives: Estimating the prevalence of accumulated HIV drug resistance in patients receiving antir...
Background. Human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of an...
Objectives: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Sa...
Objectives: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Sa...
Objectives: To determine prevalence and predictors of antiretroviral drug resistance in newly diag-n...
Objective: To evaluate the extent of HIV-1 drug resistance among drug naïve Kenyan individuals....
Introduction: Emergence of HIV-1 drug resistance may limit the sustained benefits of antiretroviral ...
Background.Human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of ant...